Zymeworks (ZYME) Return on Capital Employed (2022 - 2026)
Zymeworks (ZYME) posted Return on Capital Employed of 30.28% for Q1 2026, down 7.81% sequentially from 28.08% in Q4 2025, and up 267.0% YoY from 8.25% in Q1 2025.
Zymeworks (ZYME) Return on Capital Employed (2022 - 2026) Analysis & Trends
Zymeworks has reported Return on Capital Employed for 5 years, with the latest figure at 30.28% in Q1 2026.
- Quarterly Return on Capital Employed rose 267.0% year-over-year to 30.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30.28% (up 267.0% YoY) and the FY2025 annual result came in at 25.53%, up 608.0% from the prior year.
- Return on Capital Employed eased to 30.28% in Q1 2026 per ZYME's latest filing, from 28.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 40.44% in Q3 2023 and troughed at 35.44% in Q4 2024.
- A 5-year average of 10.18% and a median of 27.5% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 7357 bps in 2024, then jumped 1356 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 34.45% in 2022, then plunged by 178 bps to 26.92% in 2023, then sank by 32 bps to 35.44% in 2024, then climbed by 21 bps to 28.08% in 2025, then fell by 8 bps to 30.28% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 30.28%, 28.08%, and 19.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -39.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.85% |
| Mar 31, 2026 | -30.28% |
| Dec 31, 2025 | -28.08% |
| Sep 30, 2025 | -19.57% |
| Jun 30, 2025 | -21.85% |
| Mar 31, 2025 | -32.94% |
| Dec 31, 2024 | -35.44% |
| Sep 30, 2024 | -33.13% |
| Jun 30, 2024 | -28.61% |
| Mar 31, 2024 | -29.11% |
| Dec 31, 2023 | -26.92% |
| Sep 30, 2023 | 40.44% |
| Jun 30, 2023 | 36.95% |
| Mar 31, 2023 | 31.56% |
| Dec 31, 2022 | 34.45% |